Lilly nabs EU approval for Trulicity; Sinclair Pharma may sell itself; Genentech defends cancer drug shift;

@FiercePharma: U.K. gatekeepers toughest on cancer meds--and getting tougher all the time. More | Follow @FiercePharma

@CarlyHFierce: Lundbeck CEO exits in disgrace, endangering key new launches. Story | Follow @CarlyHFierce

> Eli Lilly ($LLY) won the final nod from European regulators for its diabetes treatment Trulicity, a challenger for Novo Nordisk's ($NVO) Victoza; it's planning a rollout in 2015. Release | Report

> Sinclair IS Pharma says it's considering options for the company, including selling all or part of itself, or perhaps arranging licensing and co-marketing deals. Report

> Roche's ($RHHBY) Genentech unit once again defended its decision to narrow distribution on its three best-selling cancer drugs after purchasing agent Novation placed an open letter in The New York Times. Report

> U.S. lawmakers are looking for ways to combat recent price hikes for generic drugs, including legislation that would allow imports from Canada. Report

Medical Device News

@FierceMedDev: Reva raises $25M to get CE mark for bioresorbable scaffold. Article | Follow @FierceMedDev

@VarunSaxena2: Updated with more information from Bloomberg: Stryker said to be interested in buying Smith & Nephew (once again). More | Follow @VarunSaxena2

@EmilyWFierce: $BSX sinks some funds into an Iowa-based startup developing an ablation device for atrial fibrillation. Story | Follow @EmilyWFierce

> Researchers develop 'Wi-Fi'-triggered dissolvable, implantable device for drug delivery. Story

> Covidien gets 510(k) for peripheral balloon catheter aimed at hemodialysis patients. More

Biotech News

@FierceBiotech: Cell Medica hauls in $78M to get its #cancer immunotherapy through Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Trending - UPDATED: J&J jumps into hot CAR-T field with gene-editing experts at Transposagen. Article | Follow @JohnCFierce

@DamianFierce: $BMRN + $RNA sub-question: Does drisapersen qualify for a future rare pediatric disease voucher? | Follow @DamianFierce

> Cell Medica hauls in $78M to get its cancer immunotherapy through Phase II. Story

> Novartis' troubled blood cancer drug is now less of an FDA priority. More

> Report: Woodford is diving full on into biotech with new $314M fund. Article

Biotech Research News

> Autoimmune experts discover a new pathway for multiple sclerosis R&D. Story

> U.K.'s MRC outlicenses Parkinson's discovery program to China's Yabao. More

> Nanotech team mounts a search-and-destroy mission against cancer cells. Article

> UC Irvine investigators spotlight a new class of 'chemosensitizers.' News

> Rodent studies point to a new target for ovarian cancer R&D. Story

Pharma Manufacturing News

> Merck KGaA to power India plant with coconut and cashew shells. More

> AbbVie buys API plant in Singapore where it's already building one. News

> Baxter labeling issue could leave patients short on potassium chloride. Story

> Merck manufacturing know-how brought to bear on NewLink Ebola vaccine. Item

> AstraZeneca joins Bristol-Myers, Amgen in biologics buildup. Article

And Finally... Salix Pharmaceuticals ($SLXP) says it's on the hunt for new directors for an expanded board. Release

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.